Patent Number | Title | Applicant | Opposition Date |
---|---|---|---|
EP3650019 | Fluticasone Furoate In The Treatment Of Copd | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | Jun 6, 2024 |
EP3860590 | Methods For The Treatment Of Scleroderma | ARENA PHARMACEUTICALS, INC. | Feb 29, 2024 |
EP3461474 | Dry Powder Inhalation Drug Products Exhibiting Moisture Control Properties And Methods Of Administering The Same | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | Jul 13, 2021 |
EP2228064 | Pharmaceutical Composition Containing Glycopyrrolate And A Beta2 Adrenoceptor Agonist | NOVARTIS AG | Sep 8, 2020 |
EP3148521 | Fluticasone Furoate In The Treatment Of Copd | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | Sep 8, 2020 |
EP3034073 | Use Of A Composition Comprising Formoterol And Beclometasone Dipropionate For The Prevention And/Or Treatment Of An Exacerbation Of Asthma | CHIESI FARMACEUTICI S.P.A. | Mar 4, 2020 |
EP2400950 | Pharmaceutical Formulations Comprising 4-{(1R)-2- [(6-{2-[(2,6-Dichlorobenzyl)Oxy] Ethoxy}Hexyl)Amino]-1-Hydroxyethyl}-2- (Hydroxymethyl)Phenol | GLAXO GROUP LIMITED | Feb 21, 2020 |
EP2611422 | Dry Powder Inhalation Drug Products Exhibiting Moisture Control Properties And Methods Of Administering The Same | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | Jun 14, 2019 |
EP3019153 | Dry Powder Formulation Comprising An Anticholinergic, A Corticosteroid And A Beta-Adrenergic For Administration By Inhalation | CHIESI FARMACEUTICI S.P.A. | Jun 5, 2019 |
EP1617820 | Dry Power Inhaler Devices And Dry Power Formulations For Enhancing Dosing Efficiency | VECTURA LIMITED | Dec 21, 2018 |
Feel free to send us a message here and we will get back to you